Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
essential_information
2016-07-01
Published articles
Journal：Medicine (Baltimore)
Publication type: Research Article
IF(IF): 1.87
PMID: 27428233 Link To Pubmed Full text Download
Background And Purpose
Method
We summarized the clinical characteristics of patients presenting with seizures and limbic encephalitis (LE) associated with leucinerich glioma inactivated-1 protein antibody (LGI1) in order help recognize and treat this condition at its onset. We analyzed clinical, video electroencephalogram (VEEG), magnetic resonance imaging (MRI), and laboratory data of 10 patients who presented with LGI1-LE and followed up their outcomes from 2 to 16 (9.4±4.2) months.
Conclusion
LGI1-LE may initially manifest with various types of seizures, particularly FBDS and complex partial seizures (CPS) of mesial temporal origin, and slowly progressive cognitive involvement. Clinical follow-up, VEEG monitoring, and MRI scan are helpful in early diagnosis. Immunotherapy is effective for the treatment of both seizure and LE associated with LGI1 antibody. Although mostly nonparaneoplastic, tumor screening is recommended in some cases.